Despite early reports that suggested the potential value of determining TOP1 levels in tumours, current therapeutic protocols do not take tumour expression levels of TOP1 protein or mRNA into account before giving CPT-based therapies [52]. This evidence concerns the gene TOP1 and neoplasm.